Clinical trial
Antifungal Use in Oncohematological Neutropenic Patients
NCT00386802 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00386802 |
|---|---|
| Title | Antifungal Use in Oncohematological Neutropenic Patients |
| Official title | ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Invader Fungal Infection |
| Intervention type | Drug |
| Interventions | Antifungal drug. VORICONAZOL. (VFEND®) |
| Enrollment | 115 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Oct 12, 2006 |
| Last update posted | Sep 18, 2009 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: